A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer
Oral mucositis (OM) is a common and debilitating toxicity induced by many chemotherapy (CT) regimens and by radiation to the head and neck. The purpose of this study is to determine the effectiveness of SNX-1012 in decreasing the duration of Grade 2, 3, or 4 oral mucositis (OM) according to World Health Organization (WHO) criteria.
100 项与 Mucosal Therapeutics LLC 相关的临床结果
0 项与 Mucosal Therapeutics LLC 相关的专利（医药）
100 项与 Mucosal Therapeutics LLC 相关的药物交易
100 项与 Mucosal Therapeutics LLC 相关的转化医学
